| Authors: |
Bauer S; Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany., Larkin J; Department of Medical Oncology and Hematology, The Royal Marsden Hospital, London, United Kingdom., Hodi FS; Melanoma Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MD, United States., Stephen F; Hebrew University Hadassah Medical School, The Sharett Institute of Oncology, Jerusalem, Israel.; Jacob Schachter, Sheba Medical Center at Tel Hashomer, Tel-Aviv University Medical School, Tel Aviv, Israel., Kapiteijn EHW; Department of Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands., Schwartz GK; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, United States., Calvo E; Early Phase Clinical Drug Development in Oncology, START Madrid-CIOCC, Centro Integral Oncológico Clara Campa, Madrid, Spain., Yerramilli-Rao P; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris, France., Carvajal RD; Department of Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands. |
